Every material Form 8-K Generate Biomedicines, Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Generate Biomedicines said draft copies of three posters for the European Respiratory Society Congress 2026 were made publicly available on the ERS website on August 25, 2026, before the embargo it believed would end on September 7, 2026. The posters present results from ongoing GB-0895 clinical trials, and the company has filed the final posters as Exhibit 99.1 as a precaution.
Draft posters were posted on the ERS website on August 25, 2026; the company believed the embargo would run until 6:01 p.m. Eastern time on September 7, 2026.
The ERS Congress is scheduled for September 5-9, 2026.
Posters cover Phase 1 asthma and COPD data, and the Phase 3 SOLAIRIA-1 and SOLAIRIA-2 asthma studies, with a half-life of about 98 days at 300 mg reported for the asthma data.
Generate Biomedicines reported results for the quarter ended June 30, 2026, with collaboration revenue of $6.3 million, down from $10.1 million a year earlier, and a net loss of $67.3 million, up from $56.7 million. Cash, cash equivalents, and marketable securities were $457.4 million, down from $516.6 million at March 31, 2026, and the company says it expects to need additional capital to support long-term operations, which matters to shareholders because it signals future funding needs.
Collaboration revenue was $6.3 million for the quarter, compared with $10.1 million for the same period in 2025.
Net loss was $67.3 million, compared with $56.7 million, and research and development expenses rose to $64.3 million from $59.7 million.
Cash and marketable securities totaled $457.4 million at June 30, 2026, which the company says can fund its current operating plan into the first half of 2028.
Generate Biomedicines reported first quarter 2026 results, with revenue of $7.2 million, down from $8.8 million a year earlier, and a net loss of $61.7 million, up from $44.3 million. Cash, cash equivalents and marketable securities rose to $516.6 million after its March 2, 2026 IPO, which the company says funds operations into the first half of 2028, though it expects to need additional capital.
Revenue was $7.2 million for the quarter ended March 31, 2026, compared with $8.8 million a year earlier, tied to Amgen and Novartis research programs.
Research and development expenses rose to $57.8 million from $46.8 million, driven mainly by the GB-0895 Phase 3 program in severe asthma.
Cash, cash equivalents and marketable securities were $516.6 million at March 31, 2026, versus $221.5 million at December 31, 2025, including $369.3 million in net IPO proceeds.
Net cash used in operating activities was $80.4 million, compared with $53.2 million a year earlier.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Generate Biomedicines, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →